Global David H. Crean summarizes the recent 40th annual J.P. Morgan Healthcare Conference 2022 that was held in a virtual format. Crean underlines the importance of the Conference for establishing the tone and tenor for the industry and highlights some of the biopharma topics to monitor.   39 years ago, JPM launched…

Global 2021 saw PharmaBoardroom’s network of executives and experts weighing in on some of the most pressing issues facing our industry today. See below for five of the most thought-provoking pieces, ranging from patient engagement to access solutions, infrastructure building, biomarkers, and sustainability.   A ‘Bold Vision’ of Patient Engagement The…

Europe Writing in the December edition of DIA’s Global Forum magazine, Thomas Kühler updates his August piece on the progress towards a unified HTA system in Europe and the objectives of the recently launched EUnetHTA 21 initiative.   Global Forum recently published a piece on Health Technology Assessment (HTA) in the EU and how a regulation…

Singapore Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for orphan drug registration in four ASEAN countries and what more could be done to improve it.   Regulatory authorities such…

Global David H. Crean, Managing General Partner for Coast BioVentures, updates and highlights the latest trends in the cell and gene therapy market for deal activities and financings over the past two years since his original article on the topic was published on PharmaBoardroom in June 2019.   Cell and gene…

Global PharmaBoardroom’s network of thought leaders provided some of our best-read content in 2021 on topics ranging from China’s National Reimbursement Drug List to the vaccine row that erupted between AstraZeneca and the EU, the skills that pharma leaders need in the MEA region, the year’s most prominent trends, and how…

Global PharmaBoardroom’s ten most-read executive interviews of 2021 reflect the wide scope – in terms of both geography and value chain – that our work has taken on in the past 12 months. From one of Asia’s leading regulatory bodies to some of the Middle East’s most dynamic emerging companies via…

Mexico The latest from Mexican pharma, including government talks with Indian authorities to provide low-cost medicines, a new distribution pilot program led by the military, the authorization of two Lilly monoclonal antibodies to treat COVID-19 and Bayer’s LatAm general manager comments on providing regional doctors with “the Netflix of medical information”…

Saudi Arabia Saudi Arabia’s response to COVID-19 stands up well to international comparisons in both the MENA region and globally. In recent conversation with PharmaBoardroom, Fahad Al Shebel, CEO of national medicine procurement body NUPCO, outlines some of the fundamentals behind this success story.   Extreme, But Effective, Measures Saudi Arabia took…

Global Based on IQVIA’s pharma market rankings for 2020, we give a rundown of the global top 10, key companies, important trends, and where you can go to learn more.   1. United States Way out in first place with a market value of USD 533.5 billion in sales in 2020,…

Denmark Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the US, there are five products based on Genmab science on…

Spain According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends include the fact that generics penetration in Spain has remained at a constant level for almost seven years and private…